UPDATE 03 November 2021: Please note our initial invited Guest Speaker Professor Martin Kolb is no longer able to attend the event, in his place Professor Gisli Jenkins will be giving his Inaugural Lecture for the Launch of the Margaret Turner Warwick Centre for Fibrosing Lung Disease
New talk title: ‘Curing the Incurable’
We hope to host an event with Professor Kolb in the near future and this will also be communicated through the Imperial College What’s on page as soon as possible.
This year’s Annual Margaret Turner Warwick Lecture is being delivered by Professor Gisli Jenkins. The lecture will also accompany the Inaugural launch of the Margaret Turner Warwick Centre for Fibrosing Lung Disease at the NHLI, the only Centre for Fibrosing Lung Disease in the UK.
Professor Gisli Jenkins is an NIHR Research Professor and holds the Margaret Turner-Warwick Chair of Thoracic Medicine at Imperial College London. He is based at the Guy Scadding Building at the Brompton Campus where he is Head of the Margaret Turner-Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute. Gisli also holds Honorary contracts with the Royal Brompton and Harefield NHS Foundation Trust and with the Imperial College Healthcare NHS Trust.
Prof Jenkins’ research focuses on Interstitial Lung Diseases, and Pulmonary Fibrosis in particular. His team works to understand the biological basis for the development of pulmonary fibrosis and aims to translate this understanding in to improved outcomes for patients. Gisli is the Principle Investigator of a number of longitudinal observational studies including the PROFILE study, the INJUSTIS Study, the UKILD Post COVID ILD study as well as the DEMISTIFI Multi-Morbidity consortium. He is the pulmonary fibrosis working group lead for the Genomics England Clinical Interpretation Partnership in Respiratory Medicine and the PHOSP-COVID study. In 2020 he was awarded the ERS Gold Medal in Interstitial Lung Disease.
He completed his medical training at University of Southampton before undertaking postgraduate training in Respiratory Medicine in London. During this time, he undertook basic scientific training funded by an ARC Fellowship and obtained a PhD in Biochemistry from University College, London, before doing post-doctoral studies at University of California, San Francisco, as part of an ARC Clinician Scientist Fellowship. In 2005 he moved to the University of Nottingham as a Clinical Senior Lecturer before being appointed Professor of Experimental Medicine in 2015. In 2021 he was appointed the Margaret Turner Warwick Chair of Thoracic Medicine at Imperial College London.
Professor Jenkins’ research has been published in leading academic journals including the Journal of Clinical Investigation, Lancet Respiratory Medicine, Nature Communications and Science Signalling and his research group has received funding from Academic organisations including the Medical Research Council, the NIHR, the NC3Rs, the Wellcome Trust, Arthritis Research UK and Asthma UK as well as being awarded industrial contracts in collaboration with Biogen, Galecto, GlaxoSmithKline, MedImmune, Novartis and Pliant Therapeutics.
Active in the wider research community, he is joint Editor-in-Chief of Thorax and was Chair of the Science and Research Committee until 2018. Professor Jenkins promotes public patient involvement in biomedical research and is currently a Trustee of the patient charity Action for Pulmonary Fibrosis.